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Abstract
Extensive data suggest that estradiol contributes to the development of breast cancer by acting as a 
mitogen and exerting direct genotoxic effects after enzymatic conversion to 4-hydroxyestradiol (4-
OHE2) via cytochrome P450 1B1 (CYP1B1). The mammary gland, ovary, and uterus all express 
CYP1B1. Overexpression of this enzyme has been associated with an increased risk of breast 
cancer and blockade might reduce this carcinogenic effect. For this reason, we conducted 
systematic in vitro and in vivo studies of a CYP1B1 inhibitor, TMS (2,3′,4,5′-
tetramethoxystilbene). We found that TMS blocked the enzymatic conversion of radiolabeled 
estradiol to both 2-hydroxyestradiol (2-OHE2) and 4-OHE2, but did not inhibit Cyp1b1 message 
formation. In vivo studies using mass spectrometry showed that TMS inhibited formation of 2-
OHE2 and 4-OHE2 and the resulting estrogen-DNA adducts. To examine its biologic actions in 
vivo, we investigated whether TMS could block the hyperplastic changes that occur in the 
developing breast of aromatase-transfected mice. We found that TMS induced a significant 
reduction of ductal structures in mice less than 6 months in age. In older mice, no reduction in 
breast morphology occurred. These latter studies uncovered unexpected estrogen agonistic actions 
of TMS at high doses, including a paradoxical stimulation of breast ductal structures and the 
endometrium. These studies suggest that the enzyme inhibitory properties of TMS, as well as the 
effects on developing breast, could implicate a role for TMS in breast cancer prevention, but only 
in low doses and on developing breast.
Keywords
2,3′,4,5′-Tetramethoxystilbene (TMS); Mouse mammary gland; Ductal branching; Aromatase-
transgenie mice; Cytochrome P450 1B1
Introduction
Epidemiologic studies suggest that estrogen contributes to the development of breast cancer. 
Early menarche, late menopause, high breast density, and increased plasma estrogen levels 
are all associated with an increased risk of breast cancer. A widely accepted mechanistic 
hypothesis suggests that estrogens directly activate the transcription of genes involved in 
cellular proliferation, enhancing mitosis and accelerating the rate of mutations, which lead to 
cancer. However, the enhanced proliferation induced by estrogen may not explain all of its 
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carcinogenic effects. In certain model systems, the estrogen receptor antagonist fulvestrant 
fails to block estrogen-induced neoplastic transformation [1].
Several investigators have suggested that metabolism of estrogens may influence the 
carcinogenic process through the formation of genotoxic metabolites. One pathway involves 
the conversion of estradiol (E2) to 4-hydroxyestradiol (4-OHE2) via the cytochrome P450 
enzyme CYP1B1 [2–4]. 4-OHE2 is then further metabolized to the catecholestrogen-3,4-
quinone, resulting in depurinating DNA adducts, error-prone DNA repair, and formation of 
mutations [5]. Human tissues that are regulated by hormones, such as the mammary gland, 
ovary, uterus, and prostate, all express cytochrome P450 1B1 (CYP1B1) [6–9].
Based on these considerations, researchers have sought to identify CYP1B1 inhibitors in an 
effort to find agents that would prove useful in preventing cancer modulated by this enzyme. 
Past investigations examined the stilbene family as promising lead compounds. The 
Guengerich laboratory has shown that 2,4,3′,5′-tetramethoxystilbene (TMS) is the most 
potent and selective CYP1B1 inhibitor in vitro [10]. TMS was unexpectedly found to exert 
additional biologic effects on breast cancer cell lines, inducing apoptosis through 
mitochondrial pathways [11]. This study involves a series of experiments to examine further 
the direct and indirect effects of TMS on CYP1B1 enzymatic activity and transcriptional 
regulation. In addition, we determined whether TMS alters ductal and lobular morphology in 
the developing and developed breast. We found that TMS blocked the enzymatic conversion 
of E2 to both 2-OHE2 and 4-OHE2, but does not alter Cyp1b1 message. In mice less than 6 
months of age, TMS reduced ductal and lobular formation in the developing breast. These 
effects suggest that TMS or a more potent and selective inhibitor might be useful for the 
prevention of breast cancer.
Materials and methods
Reagents and chemicals
TMS was synthesized as described previously [12]. HistoClear was from National 
Diagnostics (Atlanta, GA) and Taq DNA polymerase from Invitrogen (Carlsbad, CA). All 
other reagents were from Sigma-Aldrich (St. Louis, MO).
Measurement of CYP1B1 and CYP1A1 activities in breast cancer cells
LTED [13] or MCF-7 cells were pretreated with TCDD for 48 h to induce CYP1B1 and 
CYP1A1 activities sufficiently to allow demonstration of inhibition. Cells were incubated at 
37°C with 1.5 ml serum-free medium containing [6,7-3H]E2 (1 μCi/ml), TCDD (10 nM), the 
catechol-o-methyltransferase inhibitor OR486 (10 μM), and 4-OHE2 or 2-OHE2 (5 μM) for 
6 h. After incubation, the medium was recovered and treated with β-glucuronidase and 
sulfatase for hydrolysis of the metabolite conjugates [14]. Catecholestrogens were isolated 
[14] and separated by thin layer chromatography in a solvent containing chloroform, 
cyclohexane, and glacial acetic acid (2:2:1). Radioactivity of steroid spots was counted in a 
Beckman LS6500 scintillation counter. The conversion of radiolabeled E2 to the 4-OHE2 
and 2-OHE2 metabolites, respectively, was used to assess CYP1B1 and CYP1A1 activity.
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Aromatase-transfected mice
The previously described, MMTV-aromatase over-expressing transgenic mice were a kind 
gift from Dr. Raj Tekmal [15]. All animal experiments were conducted under Federal and 
Institutional guidelines and approved by the University of Virginia Animal Care and Use 
Committee.
TMS and letrozole treatments
TMS was administered at three different doses: low dose, 30 mg via two silastic implants of 
15 mg each; mid-dose, 60 mg via two silastic implants of 30 mg each, which were placed 
subcutaneously into the back of mice. The 30 mg implants delivered 77 microgram/kg/day 
and the 60 mg implants delivered 144 μg/kg/day (see Supplemental Fig. 1). High dose, 
subcutaneous injections at 50 mg/kg daily. Letrozole was administered by gavage at 1 
mg/kg/mouse/day.
In vivo experiments
Ovariectomy plus E2 plus TMS—Three groups were utilized including: (a) 
ovariectomy plus vehicle, (b) ovariectomy plus 130 pg/ml E2, and (c) ovariectomy plus 280 
pg/ml of E2. Owing to variations in the level of aromatase expression in breast tissue in 
these transgenic animals, we stratified according to the pre-treatment degree of breast 
hyperplasia before randomization. To accomplish this, we removed the left fourth mammary 
gland in 3-week-old mice, prepared whole mounts, and staged them into four groups based 
on degree of proliferation. The treatment protocol involved a 3-month period. Month 1: 
ovaries were removed at the start of the month and the fifth mammary gland on the right 
side obtained at the end of the month. Month 2: vehicle or estrogens were started and at the 
end of the month, the third mammary gland on the right side of each mouse was removed, 
whole mounted and assessed to quantitate ductal branching. Month 3: E2 or vehicle was 
continued and 30 mg TMS administered to groups b and c. At the end of the month, mice 
were sacrificed and the third mammary gland on the left side was removed and whole 
mounted for quantitation with Metamorph analysis.
TMS versus letrozole
The left fourth mammary glands were removed from 3-week-old mice to serve as a control 
in each of three groups. Group 1 then received vehicle for 1 month, group 2 received 60 mg 
TMS, and group 3 received 1 mg/kg/letrozole/day. At the end of the month, mammary 
glands were excised for analysis.
TMS in older animals
Low dose: TMS was given as a 30 mg silastic implant that delivered 77 μg TMS/kg/mouse/
day. High dose: TMS was given daily at 50 mg/kg via subcutaneous injection.
Cyp1b1 (mouse) PCR
Was performed as reported earlier [16].
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Measurement of 4-OHE2 and E2-adenine adducts
Analysis of estrogen metabolites was determined by UPLC coupled to a tandem mass 
spectrometer as previously described [17]. The metabolites that were analyzed are shown in 
Supplemental Table 1c, d.
Whole mount preparations
Whole mounts were prepared as described previously [18]. Whole mount photographs were 
taken using an Olympus SZX12 low magnification microscope with a 0.5× objective. 
Photographs were analyzed for tertiary ductal structures and alveolar buds (TDSABs) which 
are analogous to TDLUs in humans and for whole ductal structures (whole duct = primary 
and secondary ducts + TDSABs). A transparency film was placed on top of the whole mount 
picture and then the ductal branches excluding the lymph node, blood vessels, and squamous 
nodule were traced by hand. Transparencies were scanned and imported into Metamorph 
analysis software. Metamorph (Molecular devices, Sunnyvale, CA) was used to evaluate 
TDSABs and whole ductal structures. In addition, TDSABs were analyzed by drawing and 
counting the number of TDSABs to determine the % change in TDSABs (see Fig. 5d).
Statistical analysis
Box plot analysis was used to examine the differences between the control, 30 mg TMS-
treated, and 60 mg TMS-treated animals. Analyses compared all 2-OH metabolites in the 
three groups and all 4-OH metabolites (see Supplemental Table 1a, b for specific 
metabolites measured). The Kruskal–Wallis test was used to determine the statistical 
significance of the data, n = 57 for comparing 2-OHE2 data and n = 42 for comparing 4-
OHE2 data. Mammary gland whole mount results were expressed as means ± SEM for % 
ductal branching after treatment and % change of TDSABs between before and after 
treatment. Differences of TDSABs between before and after treatment were analyzed by 
one-way ANOVA test by using SPSS12.0 for Windows.
Results
Effect of TMS on CYP1B1 activity
As shown in Fig. 1a., TMS decreased the conversion of E2 to 4-OHE2 in a dose responsive 
fashion (Fig. 1a). We demonstrated an even greater effect on 2-OHE2 formation, indicating 
that TMS blocks CYP1A1 as well as CYP1B1. Previous reports from in vitro studies had 
suggested that TMS inhibits CYP1B1 by a reduction of CYP1B1 transcription as well as by 
blockade of its enzyme activity [19]. Such effects had never been confirmed with in vivo 
experiments; accordingly, we designed experiments to examine TMS function in an animal 
model. In vivo studies were conducted to examine the effects of TMS on mouse Cyp1b1 and 
Cyp1a1 in vivo, using measurements of 2- and 4-hydroxy metabolites of E2 as biochemical 
endpoints. To enhance the sensitivity of detection of metabolites, we utilized aromatase-
transfected mice, which synthesize large amounts of E2 in breast tissue. Mice were 
randomized into a control group, a 30 mg TMS group, and a 60 mg TMS group, and 
treatment was given via silastic implants for 8 weeks. At the end of this time, mice were 
sacrificed and the mammary glands were removed and analyzed for catecholestrogens, 
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quinone conjugates, and depurinating DNA adducts [17]. TMS inhibited the formation of 
both the 2-hydroxylated (n = 57, P = 0.003) (Fig. 1b, Supplemental Table 1a) and 4-
hydroxylated (n = 42, P = 0.03) (Fig. 1c, Supplemental Table 1b) metabolites. Taken 
together, these studies demonstrated that TMS blocks human CYP1B1, CYP1A1 (Fig. 1a) 
and mouse Cyp1b1, Cyp1a1 (Fig. 1b, c).
TMS does not regulate Cyp1b1 at the level of transcription
Previous reports from in vitro studies had suggested that TMS inhibits CYP1B1 by a 
reduction of CYP1B1 transcription. Therefore, we sought to confirm this observation in 
vivo. Mice were given either 0.3% HPC vehicle control or 50 mg/kg TMS subcutaneously 
daily for 8 weeks and breast tissue was obtained for PCR analysis. Surprisingly, TMS did 
not decrease mouse Cyp1b1 message as shown in three separate experiments (see Fig. 1d, 
compare control, leftmost striped bars, to TMS-treated, rightmost solid black bars).
Effects of TMS on cellular proliferation
Our prior studies had demonstrated that TMS reduces cell number in MCF-7 cells. As this 
agent blocks the conversion of E2 to its catechol metabolites, we questioned whether some 
of the effects of TMS might be due to reduced catecholestrogen levels. Safe et al. had 
previously reported that 2- and 4-OHE2 can exert estrogenic actions [20]. If correct, adding 
back of the catecholestrogens might partially rescue the effects of TMS on cell number. To 
examine this issue, we initially sought to confirm that the catecholestrogens could stimulate 
cell number in our experimental system. Both 2-OHE2 and 4-OHE2 enhanced cell 
proliferation in a dose responsive fashion (Fig. 2a) with peak effects between 10−7 and 10−6 
M. These effects were mediated by estrogen receptors since fulvestrant (ICI) blocked the 
proliferative effects of the catecholestrogens (Fig. 2b). We then determined whether adding 
back of the catecholestrogens would partially rescue the TMS effect on cell number. 
Addition of 10−7 M 4-OHE2 or a combination of 2-OHE2 and 4-OH E2 at 10−7 M did not 
alter the results (see Fig. 2c). These observations allowed us to conclude that the inhibitory 
effects of TMS occur independently of the blockade of E2 to the catecholestrogens.
Effects of TMS on developing breast structures
Prior published studies demonstrated that TMS could bring about apoptosis on breast cancer 
cells by invoking the intrinsic cell death pathway [11, 21]. TMS was also effective for 
reducing tumor burden in vivo [11]. Our current data indicate that TMS blocks growth in 
vitro independently of its catecholestrogen blocking effects. Therefore, it was of interest to 
determine whether TMS blocked the processes of breast development in young animals or 
maintenance in older ones. For initial experiments, we chose to examine effects on 
developing breast in a murine model with rapidly proliferating breast tissue. As ovariectomy 
reduces breast ductal development, we compared the effects of TMS to those of ovariectomy 
(oophorectomy) with and without added E2 as biologic yardsticks in all experiments. This 
experimental design obviates any effects potentially mediated through pituitary negative 
feedback. Figure 3a demonstrates the effect of ovariectomy to reduce ductal development 
over a 3-month period. Estrogen implants (130, Fig. 3b and 280 pg/ml, Fig. 3c) increased 
ductal branching in ovariectomized animals in a dose responsive fashion. During month 3, 
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TMS given along with estrogen reduced ductal structure formation (see Fig. 3 compare 3b, c 
with 4b, c). Visnal assessments were confirmed by quantitative Metamorph analysis (refer to 
Fig. 3d). The 30 mg TMS implants given during month 3 reduced ductal branching in both 
the 130 pg/ml (black bars, P = 0.01) and 280 pg/ml (gray bars, P = 0.018) groups of mice. 
To further confirm the in vitro data (see Fig. 2c), TMS exerted a direct effect rather than by 
a reduction of 4-OHE2 formation since addition of 4-OHE2 in combination with E2 and 
TMS did not rescue the reduction in ductal branching (see Supplemental Fig. 2). These data, 
taken together, demonstrate a direct TMS effect to reduce ductal development in 
oophorectomized animals replaced with E2.
TMS versus letrozole and terminal end bud formation
Ovariectomy (Oophorectomy) abrogates the ovarian release of progesterone and estrogen. 
Blockade of estrogen production with an aromatase inhibitor such as letrozole specifically 
lowers E2. With this as a rationale, we sought to examine the effect of TMS in animals with 
intact ovaries, but negligible E2 secretion and compared the effect of TMS and letrozole on 
the whole mount appearance of mammary tissue. Three-week-old intact aromatase-
transgenic mice had the left fourth mammary gland removed and whole mounted. At the end 
of the 4 weeks of treatment, the right mammary glands were removed (Fig. 4a, compare 
panels 1 and 2). As assessed visually, the major effect appeared to be a reduction of terminal 
ductal structure formation, and this occurred in both the letrozole and TMS-treated mice.
Breast effects in young versus older mice
Using animals available to us at that time, we entered animals into a study in which we gave 
30 mg TMS by silastic implant for 8 weeks in mice that ranged in age from 4 to 10 months. 
The percentage ductal branching (mean ± SEM) was found to be 6.48 ± 0.28% in the control 
group (n = 16), 5.45 ± 0.3% in the ovariectomy group (n = 16), and 6.05 ± 0.4% in the TMS 
group (n = 16). Thus, it initially appeared that development of the mammary glands was 
similar in the TMS and control groups, but a reduction was observed in the ovariectomy 
group. A closer examination of the data uncovered that only the younger animals with 
developing ducts were susceptible to TMS treatment (see Fig. 4b–d). The mean ± SEM for 
percentage change of TDS in mice younger than 6 months were +78.8 ± 31.7% for control 
group, +2.7 ± 6.7% for TMS group, and −26.9 ± 18.5% for the ovariectomy group (see Fig. 
4d).
TMS given to mice older than 5 months
To determine whether there was any effect of TMS on the mammary gland in the older 
animals, we utilized the highest dose that we had previously utilized, 50 mg/kg, given by 
subcutaneous injection over an 8-week period. This high dose of TMS was chosen because 
we expected a degree of resistance in the developed breast. Clearly, no inhibition was 
observed in these older animals treated with TMS, since stimulation was observed (Fig. 5a2 
compare before with after). We used the Metamorph program to analyze the change in 
whole ductal structures, which we defined as consisting of the large duct as well as TDSABs 
(see “Methods” and Fig. 5b). In addition, Metamorph analysis of the whole duct (Whole 
Duct Structure, see Fig. 5b, c) as well as a visual analysis of TSABs (Fig. 5d) confirmed the 
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stimulatory properties of TMS. The mean ± SEM of percentage total ductal lobular units 
(TDLUs) was 4.99 ± 0.43 in control group (n = 11) and 6.26 ± 0.36 in TMS group (n = 12) 
with the Metamorph program (Fig. 5b). Changes in alveolar buds examined also indicated a 
stimulatory effect of TMS (Fig. 5c). The mean ± SEM of percent change of alveolar buds 
were −10.1 ± 6 for the control group (n = 11), 14.2 ± 8.5 for the TMS group (n = 12), and 
−43 ± 5.2 for the ovariectomy group (n = 12) (P = 0.04 between control and TMS, P < 0.01 
between TMS and ovariectomy, and P = 0.008 between control and ovariectomy see Fig. 
5b).
In vivo toxicity of TMS
The toxicity of TMS at three different doses was tested: low dose (30 mg via silastic 
implants for 8 weeks), mid-dose (60 mg via silastic implants for 8 weeks), and high dose (50 
mg/kg via subcutaneous injection for 4 weeks). No changes in body or uterine weight were 
observed (see Supplemental Table IIa, b). However, H&E staining of the organs from the 
high 50 mg/kg TMS treatment group showed significant toxicity to the liver on histological 
sections and an increase in megakaryoctes in the spleen (but without thrombocytosis in 
blood, see Fig. 6). Whole cell blood counts were also taken (see Supplemental Table IIc). 
Interestingly, we observed estrogenic effects with endometrial stimulation (see Fig. 6), but 
without change in total uterine weight (see Supplemental Table IIa, b).
Discussion
2,3′,4′,5′-TMS was developed as a selective inhibitor of CYP1B1, based on in vitro studies 
of potency and selectivity. CYP1B1 catalyzes the conversion of E2 to 4-OHE2, a catechol 
estrogen reported to exert direct carcinogenic effects on breast [5, 22–24]. Our prior studies 
unexpectedly demonstrated a direct, pro-apoptotic effect of TMS on human breast cancer 
cells. These findings, taken together, suggested that TMS might be a promising agent to 
prevent breast cancer. For this reason, we conducted systematic studies on the effects of 
TMS on human cells in vitro and on breast structures in vivo. We report that TMS non-
selectively blocks both 2-OHE2 and 4-OHE2 formation via inhibition of cytochrome P450 
activity, but does not reduce message levels (see Fig. 1), a finding previously reported from 
in vitro studies [19]. We discovered that TMS prevents cellular proliferation (see Fig. 2c) by 
a different pathway than it uses to inhibit the cytochrome P450s.
It is of interest that our data demonstrate that catecholestrogens can stimulate breast cancer 
cells (see Fig. 2a). Previous study by Safe and coworkers had also shown the potential for 
catecholestrogens to stimulate the growth of MCF-7 and T47D, ER + breast cancer cells 
[25]. As these agents can bind to the ER, albeit with weak affinity, it is likely that these 
estrogenic effects are mediated through classical estrogen-related proliferation pathways.
As estrogen and progesterone are known to influence terminal duct structures in the breast, 
we utilized ovariectomy as a benchmark with which to compare the effects of TMS. Loss of 
ductal structures in response to ovariectomy in mice reflects the lack of estrogens and 
progesterone. Estrogens are considered to play a major role in promoting the proliferation of 
normal breast epithelium [26]. Progesterone is required for alveolar growth, but not ductal 
formation [27, 28]. When compared with ovariectomy, low dose TMS given to young mice 
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with developing breasts produced reductions both in whole duct structures and in TDSABs 
(Figs. 3, 4). However, when TMS was given to mice older than 5 months of age, it was 
found to increase TDSABs (see Fig. 5).
Our findings with respect to TMS and terminal duct structures could be important with 
respect to the genesis of breast cancer. Wellings and Jensen concluded that TDLUs are the 
principal sites of origin of dysplastic, metaplastic, hyperplastic, anaplastic, and neoplastic 
lesions of the human breast [29]. Parks also concluded that breast cancer arises in the TDLU 
[30]. Compounds such as TMS, which block TDSABs in young mice, might then be useful 
in the prevention of breast cancer.
When TMS was administered at high doses, we found it exerted estrogenic properties, 
stimulating the endometrium and formation of total duct structures as well as larger ducts in 
mice older than 5 months (see Fig. 5). Other stilbenes such as diethylstilbestrol (DES) and 
resveratrol have estrogenic activity [31–33]. DES contains hydroxyl groups in positions 
analogous to the 3 and 17 positions of E2. In contrast, all hydroxyl groups on TMS are 
converted to methyl groups, and therefore, TMS would not be expected to bind to the 
estrogen receptor nor act as an estrogen. Although Phase I CYP enzymes are best known for 
their oxidation reactions, the CYPs can catalyze a variety of reactions including O-
dealkylation [34]. Dawling and coworkers have shown that CYP1B1 is capable of 
demethylating methoxyestrogens [35]. Thus, if demethylation were to occur in vivo, 
metabolites of TMS might be estrogenic. Chun and coworker studied the metabolism of 
TMS and demonstrated a metabolite formed through the enzymatic activity of CYP1B1 
which they thought to be an O-demethylated product [19]. We are in agreement with Chun 
et al. that TMS might not only be an inhibitor of CYP1B1, but could potentially be a 
substrate for CYP1B1. If true, the O-demethylated TMS could then exert estrogen action 
similar to other stilbenes. Interestingly, TMS also stimulated the endometrium (see Fig. 6), 
but without increasing uterine size (see Supplemental Table IIa, b). This effect might also 
represent an estrogenic effect on a target tissue, perhaps also through local demethylation.
Stilbenes other than TMS have been studied extensively and exert some of the effects 
reported here. For example, resveratrol, a stilbene family member, can also inhibit the 
formation of depurinating estrogen-DNA adducts [36–38]. It should be noted, however, that 
TMS was found to be more potent than resveratrol for blocking CYP1B1 activation in vitro. 
In addition, high dose TMS was found to be relatively non-toxic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
IMS 2,4,3′,5′-Tetramethoxystilbene
CYP1A1 Cytochrome P450 1A1
Cyp1a1 Mouse cytochrome P450 1B1
CYP1B1 Human cytochrome P450 1B1
Cyp1b1 Mouse cytochrome P450 1B1
E2 Estradiol
4-OHE2 4-Hydroxyestradiol
2-OHE2 2-Hydroxyestradiol
TDLU Terminal duct lobular units
TDSABs Tertiary ductal structures and alveolar buds
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Fig. 1. 
Increasing concentrations of TMS block the activity of CYP1B1 and CYP1A1. a MCF-7 
cells were incubated with increasing concentrations of TMS in the presence of [3H]E2 and 
[3H]2-OHE2 (black circles) or [3H]4-OHE2 (black triangles) were measured as a reflection 
of enzyme activity, b, c 2-OHE1,2 and 4-OHE1,2 and their downstream metabolites were 
measured in the mammary glands of aromatase over-expressing mice treated with vehicle, 
30 or 60 mg TMS. The box plots illustrate log plots of the median values (heavy line), the 
third quartile (area above the median), the 90th percentile (the line above the 3rd quartile), 
and the maximum value (circle). All values below the medians in the treated animals are 
undetectable. Precise values are provided in Supplemental Table 1 a and b. Asterisks 
indicate the individual TMS data points achieved statistical significance when compared to 
the intact control as determined using the Wilcoxon signed-ranked test, 30 mg TMS (P = 
0.001) and 60 mg TMS (P = 0.001). The mean percentage variation between groups was 
compared using the Kruskal–Wallis non-parametric test and 2-OHE1,2 (P = 0.003) and 4-
OHE1,2 (P = 0.033). d qRT-PCR of Cyp1b1 (mouse) from aromatase-transfected mouse 
breast tissue in animals treated with vehicle or 50 mg/kg TMS. Results have been 
normalized to β-actin. The control mice are shown on the left (striped bars) and the mice 
treated with TMS are on the right (black bars)
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Fig. 2. 
The effect of estrogen metabolites, 2-OHE2 and 4-OHE2, on the growth of MCF-7 breast 
cancer cells. a 2-OHE2 (black bars) and 4-OHE2 (gray striped bars) were titrated from 10−9 
to 10−6 M. A vehicle control, ethanol (white bar), is shown on the left. b The anti-estrogen, 
ICI 182,780 (fulvestrant), blocked 2-OHE2- and 4-OHE2-stimulated growth. MCF-7 cells 
were grown as indicated in the figure and the concentrations of anti-estrogen, estrogen, and 
metabolites used were ICI at 10−8 M, E2 10−10 M, and 2-OHE2 and 4-OHE2 at 10−7 M. c 
MCF-7 cells were treated with increasing concentrations of TMS and then either 10−10 M 
E2 (black circles), 10−10 M E2 + 10−7 M 4-OHE2 (open circles) or 10−10 M E2 + 10−7 M 4-
OHE2 + 10−7 M 2-OHE2 (black triangles) were added back to the TMS-treated cells
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Fig. 3. 
30 mg of TMS caused reductions of ductal structures in oophorectomized young mice 
treated with E2. The four whole mount panels from left to right represent: 1 before 
ovariectomy, 2 1 month after ovariectomy, 3 1 month treatment with vehicle or E2, 4 1 
month treatment with vehicle or TMS plus E2. The three panels from top to bottom 
represent a vehicle treated, b 130 pg/ml E2 treated, and c 280 pg/ml E2 treated. d 
Metamorph quantitation of the reduction of ductal branching in young mice by 30 mg TMS
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Fig. 4. 
TMS reduces ductal hyperplasia from 5-month-old aromatase-transgenic mice. a From left 
to tight the panels represent: 1 before treatment whole mount, 2 after treatment whole 
mount, 3 after treatment with H and E sections shown. From top to bottom, the panels 
represent intact control, TMS given as 60 mg silastic implants, or Letrozole (CGS20267) 
given at 20 μg/mouse. b From left to right includes: 1 intact control, 2 TMS treatment in 
intact mice <5 months of age, 3 ovariectomized mice <5 months of age. c Metamorph 
analysis of whole duct structures (primary and secondary ducts + TDSABs). d Analysis 
restricted to TDSABs (tertiary ductal structures and alveolar buds). The TDSABs were 
graphed as the mean ± SE for % change of TDS. One-way ANOVA test showed a 
statistically significant difference between the TMS and control groups (P = 0.016)
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Fig. 5. 
TMS increased alveolar buds when administered to older mice at high concentrations. From 
left to right the panels represent: 1 intact control, 2 TMS treatment of intact mice >5 months 
of age, 3 ovariectomized mice >5 months of age; top panels are before treatment and bottom 
panels are after treatment. a Whole mount of No. 4 mammary gland demonstrating 
increased alveolar buds and tertiary lateral branches with 50 mg/kg/day TMS treatment, but 
not in the intact control or ovariectomy group. b Metamorph analysis was used to determine 
the change in whole duct structure (primary and secondary ducts + TDSABs) in mice older 
than 6 months of age. c Metamorph analysis of TDSABs (tertiary ductal structures and 
alveolar buds). d Visual analysis of TDSABs. The graph indicates the mean ± SE for the 
percentage change (P = 0.04 between TMS group and control, P < 0.01 between TMS and 
ovariectomy, and P = 0.008 between control and ovariectomy)
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Fig. 6. 
Evaluation of organs after treatment with high dose, 50 mg/kg TMS. Photomicrographs of 
hematoxylin and eosin stained formalin fixed, paraffin embedded slides of aromatase mouse 
organs following control injection or injection with 50 mg/kg TMS for 8 weeks
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